Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

A 66-year-old man has become the fourth person in the world to receive a genetically edited pig kidney transplant, performed ...

Eton has secured a patent from the USPTO for its ET-600 product candidate’s desmopressin oral solution formulation for ...

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

BlueCielo, a leading global provider of software solutions to monitor and control technical information throughout the asset lifecycle, today ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.